Literature DB >> 476701

Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays.

Y Nakajima, T Miyamoto, M Tanabe, I Watanabe, T Terasima.   

Abstract

The enhanced cytocidal effect of a combination of X-rays and 5-fluorouracil was investigated by means of colony-forming ability in mouse L-cells. Cells were treated with 5-fluorouracil immediately preceding (preirradiation treatment) or following (postirradiation treatment) irradiation. In either pre- or postirradiation treatment with various concentrations of the drug for a fixed time, the enhanced effect was augmented with increasing concentrations of 5-fluorouracil up to 20 microgram/ml. When cells were subjected to postirradiation treatment with a fixed concentration of drug for varying times, the cytocidal effect was further enhanced with increasing duration of drug treatment. In preirradiation treatment, however, drug treatment for longer than 3 hr did not exhibit any further enhancement. Postirradiation treatment with 5-fluorouracil to synchronous cells at various ages demonstrated enhancement at all ages during the cell cycle. The greatest enhancement was observed in the DNA-synthetic phase. Postirradiation treatment with 5-fluorouracil (2.5 microgram/ml) for 24 hr markedly reduced the width of the shoulder of the X-ray survival curve without significantly altering the slope of the exponential portion of the curve. Recovery from sublethal radiation damage was not suppressed by 5-fluorouracil when cells were treated with drug between fractionated X-ray doses. These results indicate that damages caused by 5-fluorouracil and X-rays interact additively to induce cell killing.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476701

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Multidisciplinary management of cancer of the anus.

Authors:  N D Nigro
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

2.  Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.

Authors:  Koichi Ogawa; Hitoshi Ishikawa; Katsuji Hisakura; Yuichi Hiroshima; Toshikazu Moriwaki; Takeshi Yamada; Yoshiyuki Yamamoto; Yoshimasa Akashi; Yohei Owada; Yusuke Ohara; Tsuyoshi Enomoto; Kinji Furuya; Manami Doi; Osamu Shimomura; Kazuhiro Takahashi; Shinji Hashimoto; Hideyuki Sakurai; Tatsuya Oda
Journal:  Int J Clin Oncol       Date:  2021-07-09       Impact factor: 3.402

Review 3.  Adjuvant therapy for pancreatic cancer.

Authors:  H O Douglass
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 4.  Role of radiation therapy in small cell lung cancer: a bio-clinico-pathological review and perspective.

Authors:  S Vijayakumar; K Shepard; F Thomas; J Weick; T Rice; A Mehta
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

Review 5.  Cellular pharmacology of fluorinated pyrimidines in vivo in man.

Authors:  J S Kovach; R W Beart
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

6.  Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.

Authors:  Yulia Kundel; Nicola J Nasser; Ofer Purim; Rinat Yerushalmi; Eyal Fenig; Raphael M Pfeffer; Salomon M Stemmer; Shulamith Rizel; Zvi Symon; Bella Kaufman; Aaron Sulkes; Baruch Brenner
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

Review 7.  Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.

Authors:  Koji Harada; Tarannum Ferdous; Yoshiya Ueyama
Journal:  Jpn Dent Sci Rev       Date:  2016-12-19

8.  Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.

Authors:  T Ishikawa; Y Tanaka; H Ishitsuka; T Ohkawa
Journal:  Jpn J Cancer Res       Date:  1989-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.